US Patent 8,481,546: Scope of Claims and US Patent Landscape
US Patent 8,481,546 claims a specific, stereochemically defined small-molecule compound (R)-enantiomer, a drug product formulation, and a migraine treatment method. The scope is narrow on chemical identity and broad only along three axes: salt form, pharmaceutical composition formulation, and clinical indication tied to migraine.
What exactly does US 8,481,546 claim? (Claim-by-claim scope)
Claim 1: Single-enantiomer compound (and its salts)
Claim 1 is directed to:
- The compound: (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide, and
- “or a pharmaceutically acceptable salt thereof.”
Scope boundaries implied by the claim language
- Stereochemistry is mandatory: “(R)” is part of the required structure. A racemate or the (S) enantiomer would not fall within the literal scope of Claim 1 unless covered by some other asserted claim (none is provided in the user input).
- Salt coverage is explicit: claim coverage extends to pharmaceutically acceptable salts, without limiting which acid/base salt forms are permissible.
- No Markush alternatives are provided in the claim text you provided: it is a single, fully specified structure rather than a genus.
Practical implication for enforcement
- An ANDA or other generic challenge that produces the same core scaffold but a different stereoisomer would be positioned against Claim 1’s “(R)” requirement.
- A salt-form product could be captured if it uses the claimed (R) compound core and qualifies as “pharmaceutically acceptable.”
Claim 2: Pharmaceutical composition using Claim 1
Claim 2 covers:
- A pharmaceutical composition comprising:
- a therapeutically effective amount of the Claim 1 compound (the (R) compound) and
- association with a pharmaceutically acceptable adjuvant, carrier, or diluent.
Scope boundaries implied by the claim language
- Chemical identity is locked to Claim 1: it depends on Claim 1’s (R) compound.
- The formulation component is open-ended but generic:
- “pharmaceutically acceptable adjuvant, carrier, or diluent”
- There is no limitation on route (oral, parenteral, etc.) or dosage form in the claim text you provided.
- No dosing interval, bioavailability requirement, or delivery technology is specified.
Practical implication
- Formulation variations are likely still within the claim if they remain consistent with the “therapeutically effective amount” and “carrier/diluent” language and include the claimed (R) compound.
Claim 3: Method of treating migraine
Claim 3 covers:
- A method of treating migraine by administering:
- a therapeutically effective amount of the Claim 1 compound (or a pharmaceutically acceptable salt)
- to a patient.
Scope boundaries implied by the claim language
- The medical use is limited to migraine (not broader headache disorders in the claim language you provided).
- The method is limited to administration of the Claim 1 compound or its salts.
Practical implication
- Products using the same molecule for different indications may not directly infringe this method claim.
- The claim can be implicated even if a patient population, prescriber behavior, or label differs, depending on how infringement is argued around “treating migraine.”
What is the real-world claim “shape”? (Coverage mapping)
Coverage by axis
| Axis |
What the claims cover |
What the claims do not cover (based on claim text provided) |
| Chemical identity |
One fully specified structure with (R) stereochemistry |
Any other stereoisomer ((S) or racemate) not expressly covered by the text provided |
| Salt forms |
“Pharmaceutically acceptable salt(s)” |
Non-pharmaceutically acceptable salts or unstable/unsupported forms (litigated as “pharmaceutically acceptable”) |
| Formulations |
Any composition with pharmaceutically acceptable adjuvant/carrier/diluent and therapeutic effective amount |
Non-drug-device uses, non-formulation uses (not stated), delivery system-specific claims not present in provided claim text |
| Indication |
Migraine treatment |
Other indications not stated (cluster headache, tension headache, neuropathic pain) |
How narrow is the chemical scope versus typical US patent practice?
US claim style here is structure-defined and stereospecific. Many pharmaceutical patents claim a broader genus of analogs using Markush structure ranges. The provided claim set does not do that:
- It does not list variable substituents or optional groups.
- It does not use a “compound of formula (I)” with substituent definitions.
- It locks to a single scaffold and single enantiomer.
Result: The strongest enforcement posture generally comes from matching the exact compound (including (R)) rather than arguing around close structural equivalents.
US patent landscape around 8,481,546 (what you must expect to see)
The user input includes only the asserted claims. Without bibliographic metadata (assignee, filing date, priority date, related applications, and the patent’s full text/spec), a complete, fully evidenced map of:
- continuation families,
- related US application publications,
- patent term adjustment,
- listed patents in regulatory Orange Book records,
- specific family members worldwide,
cannot be produced accurately.
However, the typical landscape mechanics for this claim type in the US are consistent and actionable for investors and BD teams:
1) Likely coexisting IP layers
For a patented small-molecule with a stereochemical element and a migraine method, the US landscape usually includes multiple layers around:
- Chemical composition claims (compound + salts)
- Formulation claims (carriers, dosage forms, therapeutic compositions)
- Use/Method claims (migraine or migraine-subtype clinical outcomes)
- Process or intermediate claims (how to make the chiral intermediate or final (R) enantiomer)
- Polymorph/crystal form claims (if the patent family discloses them)
- Combination therapy claims (if any dependents exist in the full record; not shown here)
Because the provided claim set is short (three claims), it is plausible that additional claims exist in the full patent text not included in the user input, or that other related applications exist within the same family.
2) Stacking risk and “design-around” vectors
Given Claim 1’s specificity, design-around strategies most commonly include:
- switching enantiomeric form (but that can still be blocked by other patents)
- modifying the scaffold (but that can be blocked by genericization around close structural equivalents if other broader claims exist)
- using a salt that is argued not “pharmaceutically acceptable”
- targeting a non-migraine indication (though composition and compound claims still apply)
The practical risk is whether other patents in the same family cover these vectors more broadly than this one patent.
3) Generic entry risk depends on multiple patents, not this one
In the US, generic litigation and Orange Book listings frequently involve:
- multiple patents per NDA/ANDA,
- different expiration dates based on filing and claim scope,
- use-code and method-of-use patents that can block “skinny labels,” even when composition patents expire later (or vice versa).
Even if this patent is not the last one standing, the method-of-use claim can materially affect label carve-outs.
Scope assessment for business decisions
A) Licensing posture
- Compound-level capture: Claim 1 is the anchor. Any asset that can reliably prove infringement (production, sale, offer for sale) of the exact (R) compound or pharmaceutically acceptable salt is positioned for stronger leverage.
- Formulation flexibility is limited by dependence: Claim 2’s breadth comes from generic “carrier/diluent” language but stays tethered to the exact molecule.
- Method leverage is indication-specific: Claim 3 is valuable for product positioning that supports migraine treatment.
B) Freedom-to-operate (FTO) posture
- The highest FTO sensitivity is the (R)-enantiomer and whether alternative products use the same stereochemical configuration.
- If a competitor’s compound uses the same scaffold but a different stereochemistry, the literal infringement risk on Claim 1 declines, but other patents in the family or other US patents on the molecule may still capture it.
C) Litigation posture
- Claim 1 is direct. It typically reduces ambiguity in infringement than Markush genus claims.
- Claim 3 requires proving that the administration is for treating migraine and that the administered amount is therapeutically effective.
Key Takeaways
- US 8,481,546 Claim 1 is narrow and stereospecific, covering one fully specified (R)-compound and pharmaceutically acceptable salts.
- Claim 2 extends to formulations containing the Claim 1 compound plus standard “adjuvant/carrier/diluent” language without restricting dosage form or route in the provided claim text.
- Claim 3 is a migraine method-of-use tied directly to administration of the Claim 1 compound or its salts.
- Landscape decisions should not treat this patent as standalone; the US IP stack for a small-molecule typically includes additional chemical, process, formulation, polymorph, and use patents that can extend exclusivity or create additional design-around hurdles.
FAQs
1) Does US 8,481,546 cover the (S) enantiomer?
The provided Claim 1 requires the (R) enantiomer. The text provided does not extend coverage to (S).
2) Are racemates covered?
Not on the claim language provided, because Claim 1 is limited to the (R) enantiomer.
3) Does the patent cover any migraine treatment formulation?
It covers compositions containing the Claim 1 (R) compound with a pharmaceutically acceptable adjuvant/carrier/diluent, and with a therapeutic effective amount. It does not define a specific dosage form in the provided text.
4) Can a competitor avoid Claim 3 by treating a different headache disorder?
Claim 3 is limited to “treating migraine.” Using the same compound for non-migraine indications would avoid literal infringement of Claim 3, but could still face Claim 1/2 exposure.
5) Is salt form a major scope expansion?
Yes in scope terms: Claim 1 explicitly includes “pharmaceutically acceptable salt(s),” so multiple salt variants can fall within the claim if they meet that standard.
References (cited sources)
No external sources were provided or used in generating this analysis because only the claim text was supplied.
